4133-72-6

Usage

Uses

Used in Pharmaceutical Research:
5-Bromo-4-fluoro-2-hydroxy-benzoic acid Methyl ester is used as a starting material for the synthesis of new drug compounds. Its unique structure and functional groups make it a valuable precursor in the development of pharmaceuticals with potential therapeutic applications.
Used in Agricultural Research:
In the agricultural industry, 5-Bromo-4-fluoro-2-hydroxy-benzoic acid Methyl ester is utilized as a starting material for the synthesis of agrochemicals. Its properties allow for the creation of new compounds with pesticidal or herbicidal activities, contributing to more effective and targeted crop protection solutions.
Used in Organic Synthesis:
As a building block in organic synthesis, 5-Bromo-4-fluoro-2-hydroxy-benzoic acid Methyl ester is employed in various chemical reactions to form a wide range of derivative compounds. Its versatility in synthesis makes it a valuable component in the creation of specialty chemicals, materials, and other advanced organic compounds.

Upstream product

• 345-29-9 4-fluorosalicylic acid 
• 67-56-1 methanol 
• 1644-71-9 5-bromo-4-fluoro-2-hydroxy-benzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 1159940-06-3 methyl-2-(benzyloxy)-5-bromo-4-fluorobenzoate 
• 1026876-50-5 5-bromo-4-fluoro-2-hydroxybenzamide 

Relevant academic research and scientific papers

Identification of Novel Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents with Excellent Pharmacokinetic Profiles against Drug-Resistant Pathogens

A series of conformationally constrained novel benzo[1,3]oxazinyloxazolidinones were designed, synthesized, and evaluated on their activities against Mycobacterium tuberculosis, Gram-positive bacteria, and Gram-negative bacteria. The studies identified a new compound 20aa that displayed good to excellent antibacterial and antitubercular profiles against drug-resistant TB strains (MIC = 0.48-0.82 μg/mL), MRSA (MIC = 0.25-0.5 μg/mL), MRSE (MIC = 1 μg/mL), VISA (MIC = 0.25 μg/mL), and VRE (MIC = 0.25 μg/mL) and some linezolid-resistant strains (MIC 1-2 μg/mL). Compound 20aa was demonstrated as a promising candidate through ADME/T evaluation including microsomal stability, cytotoxicity, and inhibition of hERG and monoamine oxidase. Notably, 20aa showed excellent mouse PK profile with high plasma exposure (AUC0-∞ = 78 669 h·ng/mL), high peak plasma concentration (Cmax = 10 253 ng/mL), appropriate half-life of 3.76 h, and superior oral bioavailability (128%). The present study not only successfully provides a novel benzo[1,3]oxazinyloxazolidinone scaffold with superior druggability but also lays a good foundation for new antibacterial drug development.

Benzo[1, 3]oxazin-oxazolidinone compounds, and preparation method and application thereof

The invention discloses benzo[1, 3]oxazin-oxazolidinone compounds, and a preparation method and application thereof, and belongs to the technical field of medicines. The invention specifically relates to application in preparation of drugs for treating an

APOPTOSIS SIGNAL-REGULATING KINASE INHIBITORS AND USES THEREOF

Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.

Big catkin willow acids compounds and medical use

The invention discloses a AMPK agonist activity with salicylic acid compound and its preparation method and medical use, it is the structural formula of the formula (I) compound of formula, its pharmaceutically acceptable salt or prodrug or solvate. The structure of the invention of formula (I) compound of formula activated AMPK, therefore can be used for preparing the prevention or treatment of AMPK mediated diseases.

ASK1 INHIBITING AGENTS

Provided are compounds of Formulas (I'), (I), (II') and (II), or pharmaceutically acceptable salts thereof, and methods for their use and production.

METHOD FOR PRODUCING PRECURSORS FOR L-3,4-DIHYDROXY-6- [18F] FLUOROPHENYL ALAINE AND 2- [18F] FLUORO-L-TYROSINE AND THE ALPHA-METHYLATED DERIVATIVES THEREOF, PRECURSOR, AND METHOD FOR PRODUCING L-3, 4DIHYDROXY-6- [18F] FLUOROPHENYLALANINE AND 2- [18F] FLU

Disclosed is a method for producing precursors for L-3,4-dihydroxy-6-[18F]fluorophenylalanine and 2-[18F]fluoro-L-tyrosine and the α-methylated derivatives thereof, the precursor, and to a method for producing L-3,4-dihydroxy-6-[sup